Danat Al Emarat Hospital Pioneers Teplizumab Immunotherapy for Type 1 Diabetes in the Region

Danat Al Emarat Hospital for Women & Children is proud to be among the first in the region to offer Teplizumab, a groundbreaking immunotherapy drug that delays the onset of Type 1 diabetes in at-risk individuals. Approved for use in patients aged 8 years and older, Teplizumab works by reprogramming the immune system to preserve beta-cell function, extending the period before clinical symptoms appear. 

This advancement marks one of the most significant developments in diabetes care since the discovery of insulin over a century ago. By delaying the progression of the disease, Teplizumab can help reduce the need for early insulin injections and frequent glucose monitoring — providing patients and families with a vital window of opportunity and improved quality of life. 

Dr. Summia Zaher, CEO and Medical Director at Danat Al Emarat, stated: 
“Teplizumab’s availability at our hospital highlights our continued commitment to offering the most advanced, life-changing therapies in the region. Preserving beta-cell function, even for a few years, can make a meaningful difference in how patients experience and manage Type 1 diabetes.” 

Dr. Abdulla Al Junaibi, Consultant Pediatric Endocrinologist, led the first successful case using Teplizumab on a child with diabetes-related antibodies. 
“The child’s journey has been safe, and we are pleased with the results of his blood sugar monitoring so far,” he said. 

“Being able to offer this level of care underscores our dedication to early intervention and personalized treatment pathways.” This achievement further strengthens Danat Al Emarat’s role as a leader in pediatric endocrinology and reinforces its mission to bring cutting-edge innovations in diabetes prevention and care to the UAE and the wider region.